10-K: AXIM Biotechnologies Focuses on Eye Health Diagnostics, Reports Full Year 2023 Results

AXIM Biotechnologies shifts its strategic focus to commercializing FDA-cleared Dry Eye Disease (DED) diagnostic systems, aiming for positive cash flow by the end of 2023.

Summary

• AXIM Biotechnologies is now prioritizing the commercialization of its FDA-cleared Dry Eye Disease (DED) diagnostic system.
• The company has acquired two FDA-cleared 510(k) tests for dry eye disease and has developed a third assay internally.
• AXIM's focus is on point-of-care testing for DED, aiming to establish this as the new standard of care.
• The company has signed a supply agreement with IUL SA for iPeak DED readers and has an exclusive global commercialization agreement with Versa Ophthalmics, LLC.
• AXIM is also developing a quantitative MMP-9 test for DED, with clinical studies planned for the third quarter of 2024.
• The company is working towards obtaining a CLIA waiver for its tests, which is expected to significantly increase demand.
• AXIM's financial results for 2023 show revenues of $39,518 and a net loss of $8,059,682.
• The company has a working capital deficit of $5,821,960 and an accumulated deficit of $72,184,858.
• AXIM is dependent on shareholder loans, private placements, and registered offerings for funding.
• The company has identified a going concern issue due to its financial position.

Sentiment

Score: 4

Explanation: The document highlights a strategic shift towards a promising market with key partnerships, but the significant financial losses, going concern issue, and dependence on external funding create a negative outlook.

Positives

• The company has a clear strategic focus on the DED market, which is a large and growing market.
• AXIM has secured key partnerships for distribution and supply of its diagnostic products.
• The company has a pipeline of new diagnostic tests under development.
• AXIM has a patented tear collection system.
• The company has received three patent allowances from the USPTO.
• The company has a revenue generating agreement with Versa Ophthalmics.

Negatives

• The company has a significant net loss of $8,059,682 for 2023.
• AXIM has a substantial working capital deficit of $5,821,960.
• The company has an accumulated deficit of $72,184,858.
• There is a going concern issue due to the company's financial position.
• The company is dependent on external funding sources.
• The company has limited cash on hand.

Risks

• The company's ability to continue as a going concern is dependent on securing additional funding.
• There is a risk that the company may not be able to obtain a CLIA waiver for its tests.
• The company faces competition from other diagnostic companies.
• The company's financial results are subject to volatility.
• The company is dependent on key personnel.
• The company is subject to regulatory risks.
• The company is subject to supply chain risks.
• The company is subject to cybersecurity risks.

Future Outlook

The company plans to complete clinical trials for CLIA waivers, generate positive reviews from eye care professionals, penetrate the ophthalmologist and optometrist marketplace, identify strategic acquisition targets, and reach a positive cash flow run rate by the end of 2023.

Management Comments

• The company believes that the acquisition of these FDA 510(k) cleared diagnostic products, a waiver and the distribution partnership we have with Versea will allow the business to grow at a rapid pace.
• The Company believes it offers the most potential for rapid and immediate growth, which could lead to ultimate profitability for the organization.
• The commercial launch of the Companys IgE and Lactoferrin tests mark the evolution of AXIM as a development-stage biotech company to a revenue generating healthcare organization.

Industry Context

The company is operating in the rapidly growing market for dry eye disease diagnostics, which is estimated to reach $6.1 billion by 2024. The company's focus on point-of-care testing and quantitative analysis positions it well in this competitive landscape.

Comparison to Industry Standards

• The company competes with Quidel, TearLab, and other companies in the dry eye disease diagnostic market.
• AXIM's tests offer quantitative analysis, which is preferred over the qualitative tests offered by some competitors.
• The company's focus on point-of-care testing aligns with the industry trend towards more convenient and accessible diagnostics.
• The company's financial results are not comparable to established companies in the industry, as it is still in the early stages of commercialization.

Management Changes

Legal Proceedings

• The company settled a patent infringement suit during 2023, resulting in a loss of $955,000.
• The company was involved in litigation with Innovative Medical Supplies, LLC, which has been settled with a cash payment, a sales participation payment, and the issuance of restricted shares.

Related Party Transactions

• The company has an employment agreement with Catalina Valencia at a rate of $15,000 per month.
• The company has a consulting agreement with Glycodots LLC for the services of Dr. Sergei A. Svarovsky at a rate of $15,000 per month.
• The company has a convertible note payable to John Huemoeller, its CEO.
• The company has a convertible note payable to Medical Marijuana, Inc., a major shareholder.

Stakeholder Impact

• Shareholders face the risk of dilution due to potential equity offerings.
• Employees may be impacted by potential cost-cutting measures.
• Customers may benefit from the company's focus on DED diagnostics.
• Suppliers may be impacted by the company's financial challenges.
• Creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

• The company plans to complete clinical trials to prove the accuracy and ease of use to achieve CLIA waivers.
• The company plans to generate positive, peer reviewed reviews by eye care professionals as to the performance and ease of use.
• The company plans to penetrate the ophthalmologist and optometrist marketplace through its partner with its industry-changing DED diagnostic technology.
• The company plans to identify potential strategic acquisition targets to accelerate its DED diagnostic applications and capabilities expansion.
• The company plans to grow its DED business to reach a positive cash flow run rate by the end of 2023 and build its profitability beyond.

Key Dates

Keywords

Dry Eye Disease, DED, Diagnostics, Ophthalmology, Point-of-Care, Lactoferrin, IgE, MMP-9, CLIA Waiver, Lateral Flow Assay, Biomarkers, Eye Health, Diagnostic Tests, Healthcare, Medical Devices